Compare MasTec Inc (MTZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Zimmer Biomet Holdings Inc — how do they compare? MasTec Inc trades at $240.68 (market cap $19.77B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: MasTec Inc and Zimmer Biomet Holdings Inc are close in size by market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | ZBH | |
|---|---|---|
Market Cap | $19.77B | $17.97B |
Sector | Technology | Health |
52-Week High | $437.51 | $104.26 |
52-Week Low | $189.18 | $79.58 |
Enterprise Value | $22.69B | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $246.18, up 3.79% today, with strong analyst support (88.9% buy ratings) and a consensus price target of $436.50. The stock shows bearish technical signals but benefits from record $21.4B backlog and AI infrastructure exposure. Recent Q2 2026 earnings missed expectations slightly, though revenue grew 23% year-over-year. The company raised its 2026 outlook, highlighting expanding data center capabilities and power delivery growth.
MTZ presents a growth opportunity driven by infrastructure demand and AI-linked projects, but faces risks from premium valuation (P/E 39.2), weak cash flow trends, and communications segment softness. Investors should weigh strong institutional interest against execution challenges in a competitive market.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
